期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

脯氨酸羟化酶抑制剂的研究进展 被引量：7

Recent Progress of Prolyl Hydroxylase Domain Inhibitors
原文传递
导出
摘要 低氧诱导因子(hypoxia-inducible factor,HIF)是细胞适应低氧环境的关键性转录因子,在组织贫(缺)血和炎症性疾病中稳定表达,对缓解病情具有重要作用。脯氨酸羟化酶(proline hydroxylase domain,PHD)能实现HIF的羟基化,是体内降解HIF的最主要蛋白酶。PHD抑制剂可以有效增加体内HIF蛋白含量,对于贫血及炎症性疾病治疗具有积极意义。本研究对小分子PHD抑制剂的最新进展进行综述。 Hypoxia inducible factor（HIF） is the key transcriptional factor of cellular response to hypoxia and plays a critical role in hypoxia related diseases. When tissue ischemic and inflammation occured, HIF stabilization can be observed and beneficial to tissue stress and injury. Prolyl hydroxylase domain（PHD） selectively hydroxylate proline residues of HIF and act as the most important proteasomal degradation enzyme for HIF in vivo. Thus, PHD inhibition is effective in the treatment of ischemic and inflammatory events through HIF stabilization. In this short review, we will introduce the recent progress of PHD inhibitors.
作者 李姗 盛荣 胡永洲
机构地区 浙江大学药学院
出处 《中国现代应用药学》 CAS CSCD 2015年第10期1277-1285,共9页 Chinese Journal of Modern Applied Pharmacy
基金 国家自然科学基金面上项目(21072171)
关键词 低氧 低氧诱导因子 脯氨酸羟化酶 脯氨酸羟化酶抑制剂 hypoxia hypoxia-inducible factor prolyl hydroxylase domain prolyl hydroxylase domain inhibitors
分类号 R977.3 [医药卫生—药品]
  • 相关文献

参考文献65

  • 1ELTZSCHIG H K, BRATTON D L, COLGAN S P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases [J]. Nat Rev Drug Discov, 2014, 13(11): 852-869.
  • 2RABINOWITZ M H. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses [J]. J Med Chem, 2013, 56(23): 9369-9402.
  • 3TIAN Y M, MOLE D R, RATCLIFFE P J, et al. Characterization of different isoforms of the HIF prolyl hydroxylase PHDI generated by alternative initiation [J]. Biochem J, 2006, 397(1): 179-186.
  • 4SEMENZA G L, WANG G L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation [J]. Mol Cell Biol, 1992, 12(12): 5447-5454.
  • 5ROGERS J L, BAYEH L, SCHEUERMANN T H, et al. Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor [J]. J Med Chem, 2013, 56(4): 1739-1747.
  • 6WANG G L, JIANG B H, RUE E A, et al. Hypoxia-inducible factor l is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension [J]. Proc Natl Acad Sci USA, 1995, 92(12): 5510-5514.
  • 7MOLE D R, BLANCHER C, COPLEY R R, et al. Genome-wide association of hypoxia-indueible factor (HIF)-lalpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts [J]. J Biol Chem, 2009, 284(25): 16767-16775.
  • 8KIM J W, TCHERNYSHYOV I, SEMENZA G L, et al. HIF-l-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia [J]. Cell Metab, 2006, 3(3): 177-1785.
  • 9PAPANDREOU I, CAIRNS R A, FONTANA L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption [J]. Cell Metab, 2006, 3(3): 187-197.
  • 10ORTIZ-BARAHONA A, VI LLAR D, PESCADOR N, et al.Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction [J]. Nucleic Acids Res, 2010, 38(7): 2332-2345.

二级参考文献11

  • 1SHANNON A M, BOUCHIER-HAYERS D J, CONDRON C M, et al. Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies [J]. Cancer Treat Rev, 2003, 29(4): 297-307.
  • 2SEMENZA G L, AGANI F, BOOTH G, et al. Structural and functional analysis of hypoxia-inducible factor-1 [J]. Kid Int, 1997, 51(2): 553-555.
  • 3LIN C, MCGOUGH R, ASWAD B, et al. Hypoxia induces HIF-1 alpha and VEGF expression in chondrosarcoma cells and chondrocytes [J]. J Orthop Res, 2004, 22(6): 1175-1181.
  • 4MONGE A, PALOP J A, CERAIN A L, et al. Hypoxia- selective agents derived from Quinoxaline 1,4-di-N-oxides [J]. J Med Chem, 1995, 38(10): 1786-1192.
  • 5MONGE A, MARITINEZERESPO F J, DECERAIN A L, et al. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1, 4-di-N-oxides [J]. J Med Chem, 1995, 38(22): 4488-4494.
  • 6WENG Q, ZHANG J, CAO J, et al. Q39, a quinoxaline 1,4-di-N-oxide derivative, inhibits hypoxia-inducible factor-1 alpha expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells [J]. Invest New Drugs, 2011, 29(6): 1177-1187.
  • 7WENG Q, WANG D, GUO P, et al. Q39, a novel synthetic Quinoxaline 1,4-di-N-oxide compound with anti-cancer activity in hypoxia [J]. Eur J Pharmacol, 2008, 581(3): 262-269.
  • 8BROWN J M. Exploiting the hypoxic cancer cell: mechanisms and therapentic strategies [J]. Mol Med Today, 2000, 6(4): 157-162.
  • 9FELSDER D, AGANI F, IYER N V, et al. Reciprocal positive regulation of hypoxia-inducible factor 1 alpha and insulin-like growth factor 2 [J]. Cancer Res, 1999, 59(16): 3915-3918.
  • 10CHANG L, KARIN M. Mammalian MAP kinase signaling cascades [J]. Nature, 2001(410): 37-40.

同被引文献112

引证文献7

二级引证文献32

中国现代应用药学
2015年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部